The Weekly Term Sheet (45)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
The Return of Royalty
On 19 November, as the Jefferies London Healthcare Conference closes for the day, a different conversation begins. Registration for our
Fund of the Week: Lilly Ventures – Eli Lilly's Strategic Biotech Investor
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Company of the week: Hemab Therapeutics
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Multiple Royalty Streams on a Single Drug: Practical Realities
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Royalty Stream Sales and Buybacks in Pharma Financing
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
China's Venture Capital Landscape in 2025 – Slump and Retreat
China's biotech venture capital (VC) sector in 2025 is recovering from a deep slump. After peaking at $15.
The Weekly Term Sheet (44)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Tax-Neutral Demerger - A case study
DISCLAIMER
This article is provided for informational and educational purposes only. It does not constitute legal, financial, tax, or investment
Fund of the Week: Curie.Bio
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
